logo
Search
  • HOME
  • HOT TOPICS
  • LATEST NEWS
  • PRIVACY POLICY
Search

U.S. FDA approves Amgen's biosimilar version of J&J's psoriasis drug

ADVERTISEMENT
U.S. FDA approves Amgen's biosimilar version of J&J's psoriasis drug © Reuters. FILE PHOTO: An Amgen sign is seen at the company's office in South San Francisco, California October 21, 2013. REUTERS/Robert Galbraith/File Photo   AMGN -2.85% Add to/Remove from Watchlist Add to Watchlist Add Position

Position added successfully to:


 
+ Add another position Close JNJ +0.89% Add to/Remove from Watchlist Add to Watchlist Add Position

Position added successfully to:


 
+ Add another position Close

(Reuters) - The U.S. Food and Drug Administration on Tuesday approved Amgen (NASDAQ:AMGN)'s biosimilar version of Johnson & Johnson (NYSE:JNJ)'s blockbuster psoriasis treatment, Stelara, for multiple inflammatory diseases.


Despite the FDA approval, Amgen's treatment is expected to be launched in 2025 as part of a legal settlement between the two companies earlier this year to delay the entry of the therapy.



Biosimilars are close copies of complex biological drugs.


Stelara, introduced in 2009, has been J&J's top-selling drug since 2019, with sales reaching $9.7 billion in 2022.


U.S. FDA approves Amgen's biosimilar version of J&J's psoriasis drug  

RELATED ARTICLE

Cancel Subscriptions on iPhone
Cancel Subscriptions on iPhone

Cancel Subscriptions on iPhone

Holidays at home for record number of Chinese as economic slowdown bites
Holidays at home for record number of Chinese as economic slowdown bites

3/3© Reuters. Tourists rest on the Bund ahead of the National Day holiday, in Shanghai, China Sept

©2025 Finance Guru All Rights Reserved

Privacy Policy

Terms of Service

Contact us at : service